Artiva Biotherapeutics, Inc. Unrealized Gain (Loss) on Derivatives
Artiva Biotherapeutics, Inc. (ARTV) reported Unrealized Gain (Loss) on Derivatives of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-03-10
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2024-12-31 was $0.00.
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2024-09-30 was -$977.00K.
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2024-06-30 was -$2.35M.
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2024-03-31 was -$268.00K.
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2025 was $0.00.
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2024 was -$3.60M.
- Artiva Biotherapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2023 was -$707.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$977.00K derived: sum of 2 quarters · filed 2026-03-10 | -$3.33M derived: sum of 3 quarters · filed 2026-03-10 | -$3.60M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$977.00K 10-Q · filed 2025-11-12 | -$3.33M derived: sum of 2 quarters · filed 2025-11-12 | -$3.60M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$2.35M 10-Q · filed 2025-08-06 | -$2.62M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$268.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$707.00K 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |